SKIN Strangle Strategy
SKIN (SkinHealth Systems Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.
SKIN (SkinHealth Systems Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $83.8M, a beta of 1.07 versus the broader market, a 52-week range of 0.551-2.69, average daily share volume of 2.1M, a public-listing history dating back to 2020, approximately 613 full-time employees. These structural characteristics shape how SKIN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.07 places SKIN roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on SKIN?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
SKIN snapshot
As of August 14, 2026, spot at $0.67, ATM IV 86.40%, IV rank 25.09%, expected move 24.77%. The strangle on SKIN below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on SKIN specifically: SKIN IV at 86.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a SKIN strangle, with a market-implied 1-standard-deviation move of approximately 24.77% (roughly $0.17 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SKIN expiries trade a higher absolute premium for lower per-day decay. Position sizing on SKIN should anchor to the underlying notional of $0.67 per share and to the trader's directional view on SKIN stock.
SKIN strangle setup
The SKIN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SKIN at $0.67 on that close, the first option leg uses a $0.70 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SKIN chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SKIN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $0.70 | N/A |
| Buy 1 | Put | $0.64 | N/A |
SKIN strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
SKIN strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on SKIN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on SKIN
Strangles on SKIN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SKIN chain.
SKIN thesis for this strangle
The market-implied 1-standard-deviation range for SKIN extends from approximately $0.50 on the downside to $0.84 on the upside. A SKIN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SKIN IV rank near 25.09% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SKIN at 86.40%. As a Healthcare name, SKIN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SKIN-specific events.
SKIN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SKIN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SKIN alongside the broader basket even when SKIN-specific fundamentals are unchanged. Always rebuild the position from current SKIN chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on SKIN?
- A strangle on SKIN is the strangle strategy applied to SKIN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SKIN stock at $0.67 on the most recent close, the strikes shown on this page are snapped to the nearest listed SKIN chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are SKIN strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SKIN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 86.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SKIN strangle?
- The breakeven for the SKIN strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The SKIN market-implied 1-standard-deviation expected move in the same options snapshot is approximately 24.77%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on SKIN?
- Strangles on SKIN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SKIN chain.
- How does current SKIN implied volatility affect this strangle?
- SKIN ATM IV is at 86.40% with IV rank near 25.09%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.